{"preliminary_commentary":{"by_channel":{"bluesky_thread":8},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT01957436\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"PEACE 1","nct_id":"NCT01957436","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=peace-1-nct01957436. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"PEACE1","arms":[{"description":"androgen deprivation therapy + docetaxel","label":"Arm A","type":"ACTIVE_COMPARATOR"},{"description":"androgen deprivation therapy + docetaxel + abiraterone acetate + prednisone","label":"Arm B","type":"EXPERIMENTAL"},{"description":"Arm A + radiotherapy","label":"Arm C","type":"EXPERIMENTAL"},{"description":"Arm B + radiotherapy","label":"Arm D","type":"EXPERIMENTAL"}],"collaborators":["Janssen-Cilag Ltd.","European Organisation for Research and Treatment of Cancer - EORTC","Ipsen","Sanofi"],"completion_date":{"date":"2032-12","type":"ESTIMATED"},"conditions":["Metastatic Prostate Cancer"],"enrollment":{"count":1173,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"abiraterone acetate","otherNames":["Zytiga"],"type":"DRUG"},{"name":"radiotherapy","otherNames":[],"type":"RADIATION"},{"name":"Androgen Deprivation Therapy","otherNames":[],"type":"OTHER"},{"name":"Docetaxel","otherNames":[],"type":"DRUG"}],"last_update":"2024-11-12","lead_sponsor":"UNICANCER","official_title":"A Prospective Randomised Phase III Study Of Androgen Deprivation Therapy With Or Without Docetaxel With Or Without Local Radiotherapy With Or Without Abiraterone Acetate And Prednisone In Patients With Metastatic Hormone-Naïve Prostate Cancer","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2021-08-18","type":"ACTUAL"},"primary_outcomes":[{"measure":"Survival","timeFrame":"7.5 years after the first inclusion"},{"measure":"Survival","timeFrame":"9.5 years after the first inclusion"}],"references":[{"citation":"Alyamani N, Clementel E, Sargos P, Blanchard P, Supiot S, Ronchin P, Pommier P, Duberge T, Silva M, Hammoud Y, Hasbini A, Khalifa J, Gnep K, Scrase C, Saez J, Vieillevigne L, Christiaens M, Zilli T, Ribault H, Bossi A, Fizazi K, Andratschke N. Radiotherapy quality assurance for the PEACE 1 trial: An individual case review analysis. Radiother Oncol. 2025 May;206:110780. doi: 10.1016/j.radonc.2025.110780. Epub 2025 Feb 7.","pmid":"39924002","type":"DERIVED"},{"citation":"Roubaud G, Kostine M, McDermott RS, Bernard-Tessier A, Maldonado X, Silva M, Flechon A, Berthold DR, Ronchin P, Tombal BF, Mourey L, Gravis G, Escande A, Abadie-Lacourtoisie S, Maurina T, Climent MA, Ribault H, Bossi A, Foulon S, Fizazi K. Assessment of bone mineral density in men with de novo metastatic castration-sensitive prostate cancer treated with or without abiraterone acetate plus prednisone in the PEACE-1 phase 3 trial. Eur J Cancer. 2025 Mar 11;218:115293. doi: 10.1016/j.ejca.2025.115293. Epub 2025 Feb 6.","pmid":"39923274","type":"DERIVED"},{"citation":"Fizazi K, Foulon S, Carles J, Roubaud G, McDermott R, Flechon A, Tombal B, Supiot S, Berthold D, Ronchin P, Kacso G, Gravis G, Calabro F, Berdah JF, Hasbini A, Silva M, Thiery-Vuillemin A, Latorzeff I, Mourey L, Laguerre B, Abadie-Lacourtoisie S, Martin E, El Kouri C, Escande A, Rosello A, Magne N, Schlurmann F, Priou F, Chand-Fouche ME, Freixa SV, Jamaluddin M, Rieger I, Bossi A; PEACE-1 investigators. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 x 2 factorial design. Lancet. 2022 Apr 30;399(10336):1695-1707. doi: 10.1016/S0140-6736(22)00367-1. Epub 2022 Apr 8.","pmid":"35405085","type":"DERIVED"}],"start_date":{"date":"2013-11-13","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Phase III Study for Patients With Metastatic Hormone-naïve Prostate Cancer","url":"https://clinicaltrials.gov/study/NCT01957436"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/peace-1-nct01957436"}